Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1226 ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Gail Cohen – Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance B ...

| --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Second Quarter 2022 | | | | Financial Results and Business Update | | | | August 4, 2022 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are | | | registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President and Chief Business Officer Rick Graham – Senior Vice President-Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Ben Ricard – Needham & Company David Risinger – SVB Securities Opera ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-122662 ...

| --- | --- | |----------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | First Quarter 2022 Financial Results and Business Update | | | May 5, 2022 | | THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2022 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033 THERAVANCE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Cayman Islands 98-1226628 (Sta ...

| --- | --- | |-------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fourth Quarter and Full Year 2021 Financial Results and Business Update | | | February 23, 2022 | | THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Commercial and Medical Affairs Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Marc Frahm – Cowen Anupam Rama – J.P. Morgan Douglas Tsao – H.C. Wainwright Liisa Bayko – E ...

JP Morgan Healthcare Conference January 13, 2022 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2022 Theravance Biopharma. All rights reserved. Forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 199 ...